12/05/2026
Protein-protein interactions were once considered undruggable, but that's changing.
With an estimated 650,000 PPIs in the human body, they represent a vast and largely untapped space for therapeutic development. Their large, flat binding surfaces make them notoriously difficult to target with traditional tools like antibodies or small molecules.
Optimers offer an alternative. Unlike antibodies, they're stable in the cytosol, can cross cell membranes, and can be tailored to target either the PPI interface directly (competitive inhibition) or a separate allosteric site.
Our Optimer platform has already demonstrated this in action, generating aptamers to the HSV-2 gD envelope protein that inhibited viral cell entry by ~90% in vitro.
The undruggable is becoming druggable. https://aptamergroup.com/aptamers-as-protein-protein-interaction-inhibitors/
